Product
Dactinomycin
Aliases
Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1, Actinomycin IV (8 other aliases)
Name
DACTINOMYCIN
INN Name
dactinomycin
FDA Approved
Yes
11 clinical trials
5 organizations
1 drug
23 indications
2 documents
Indication
RhabdomyosarcomaIndication
Alveolar RhabdomyosarcomaIndication
Spindle Cell/Sclerosing RhabdomyosarcomaIndication
Wilms TumorIndication
Botryoid-type Embryonal RhabdomyosarcomaIndication
Spindle Cell RhabdomyosarcomaIndication
Gestational Trophoblastic TumorIndication
Gestational Trophoblastic NeoplasiaIndication
Invasive MoleIndication
ChoriocarcinomaIndication
Testicular NeoplasmsIndication
Beckwith-Wiedemann SyndromeIndication
Rhabdoid Tumor of the KidneyIndication
Adult RhabdomyosarcomaIndication
Childhood Embryonal RhabdomyosarcomaIndication
Childhood Soft Tissue SarcomaIndication
SarcomaIndication
Adult Soft Tissue SarcomaIndication
Stage III Adult Soft Tissue SarcomaDrug
actinomycin DClinical trial
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative RhabdomyosarcomaStatus: Recruiting, Estimated PCD: 2030-12-31
Clinical trial
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms TumorsStatus: , Estimated PCD: 2016-06-30
Clinical trial
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)Status: Not yet recruiting, Estimated PCD: 2031-02-13
Clinical trial
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Prospective，Multicenter，Randomized Trial of Biweekly Single-dose Actinomycin-D Versus Multi-day Methotrexate Protocol for the Treatment of Low-risk Gestational Trophoblastic NeoplasiaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
GAMEC-SHORT (S) & GAMEC-ANTHRACYCLINE(A) (Combination Chemotherapy With GCSF, Actinomycin-D, Methotrexate, Etoposide and Cisplatin) Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)Status: Completed, Estimated PCD: 2013-06-01
Clinical trial
Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms TumorStatus: , Estimated PCD: 2016-12-31
Clinical trial
A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk DiseaseStatus: Recruiting, Estimated PCD: 2034-10-01
Clinical trial
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)Status: Completed, Estimated PCD: 2014-12-31
Clinical trial
Treatment for Very Low and Standard Risk Favorable Histology Wilms TumorStatus: Active (not recruiting), Estimated PCD: 2014-12-31
Organization
Prasco LaboratoriesOrganization
Hisun Pharmaceuticals USA, Inc.Document
DailyMed Label: DACTINOMYCINOrganization
Eugia US LLCOrganization
XGen Pharmaceuticals DJB, Inc.Document
DailyMed Label: CosmegenOrganization
Recordati Rare Diseases, Inc.